The Food and Drug Administration rescinded the ANCHOR study special protocol that had been granted to Amarin Corp. (Nasdaq: AMRN) for Vascepa sending the stock price down 29 cents to $1.81.
Amarin's Special Protocol Status Rescinded
October 30, 2013 at 18:10 PM EDT
